CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney...
Phase 3
Birmingham, Alabama, United States and 13 other locations
The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease...
Phase 2
Birmingham, Alabama, United States and 31 other locations
Primary Objective:Evaluate the effect of Hectorol® capsules in reducing elevated levels of intact parathyroid hormone (iPTH).Secondary Objectives:* E...
Phase 3
Birmingham, Alabama, United States and 29 other locations
CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney...
Phase 2
Birmingham, Alabama, United States and 48 other locations
tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...
Phase 2, Phase 3
Birmingham, Alabama, United States and 312 other locations
(for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.Parti...
Phase 3
Birmingham, Alabama, United States and 850 other locations
of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/ ...
Phase 3
Birmingham, Alabama, United States of America and 845 other locations
The ASSIST study is a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subj...
Phase 2
Birmingham, Alabama, United States and 29 other locations
The ASSIST study is a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subj...
Phase 2
Birmingham, Alabama, United States and 29 other locations
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...
Phase 3
Birmingham, Alabama, United States and 135 other locations
Clinical trials
Research sites
Resources
Legal